FATE — Fate Therapeutics Share News
0.000.00%
Last trade - 00:00- $252.82m
- $110.94m
- $6.65m
Fate Therapeutics slumps on terminating deal with J&J unit
Brief: Fate Therapeutics - Estimates It Will Incur Charges Of Approximately $15 Million For Severance And Other Employee Termination-Related Costs In Q1 Of 2023
Cathie Woods' Ark ETF adds more Tesla shares as prices plunge
U.S. RESEARCH ROUNDUP- Amgen, Coupa Software, Zebra Technologies
Brief: Fate Therapeutics Highlights Ipsc-Derived, Off-The-Shelf Car Nk Cell Programs For Multiple Myeloma
Brief: Fate Therapeutics Announces Exercise By Ono Pharmaceutical Of Option To Her2-Targeted Car T-Cell Product Candidate For Solid Tumors
Fate Therapeutics Inc reports results for the quarter ended in September - Earnings Summary
Brief: Fate Therapeutics To Present Clinical And Preclinical Data For Ipsc Product Platform At The 2022 Ash Annual Meeting
Fate Therapeutics Inc expected to post a loss of 89 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP- Coca-Cola, Five9, Texas Instruments
Brief: Fate Therapeutics Announces Preclinical Publication Highlighting Derivation Of Cd8αβ T Cells From Tcr-Car+ Induced Pluripotent Stem Cells
U.S. RESEARCH ROUNDUP-CF Industries Holdings, Ping Identity Holding, Trupanion
Brief: Fate Therapeutics Reports Second Quarter 2022 Financial Results
U.S. RESEARCH ROUNDUP-Bank Ozk, Bunge, Littelfuse
Brief: Fate Therapeutics Appoints Brian T. Powl As Chief Commercial Officer
Brief: Fate Therapeutics Announces Expansion Of Solid Tumor Collaboration With Ono Pharmaceutical For Off-The-Shelf, Ipsc-Derived Car Nk And Car T-Cell Cancer Immunotherapies
U.S. RESEARCH ROUNDUP-Aeglea Bio Therapeutics, Ecolab, Martin Marietta Materials
U.S. RESEARCH ROUNDUP-Eli Lilly, Gilead Sciences, Upwork
Fate Therapeutics Inc reports results for the quarter ended in March - Earnings Summary